Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 18/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 18/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.53 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.47 |
| ▸ | CHRNG | P07510 | 1/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.47 |
| ▸ | CHRND | Q07001 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5688899 | 0.90 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL5995209 | 0.85 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL5996659 | 0.75 | CHRNB2 (0.77) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5688759 | 0.75 | CHRNB2 (0.74) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL5997315 | 0.72 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL5997987 | 0.71 | CHRNB2 (0.79) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL7140369 | 0.71 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Hydrochloric Acid SCHEMBL5995466 | 0.70 | CHRNB2 (0.77) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5685749 | 0.69 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL6782044 | 0.69 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122534-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2006-10-17 | — | — | US | claimed |
| EP-1076650-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2004-02-04 | — | — | EP | claimed |
| US-6462035-B1 | BINDING TO NEURONAL NICOTINIC ACETYLCHOLINE SPECIFIC RECEPTOR; MODULATING CHOLINERGIC FUNCTION; REDUCING NICOTINE ADDICTION; INFLAMMATORY AND IRRITABLE BOWEL SYNDROME, SPASTIC DYSTONIA, CHRONIC AND ACUTE PAIN, EATING DISORDERS | PFIZER INC. | 2002-10-08 | — | — | US | claimed |
| US-7122534-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2006-10-17 | — | — | US | disclosed |
| US-20040167149-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2004-08-26 | — | — | US | disclosed |
| US-6706702-B2 | FOR THERAPY OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | PFIZER INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1076650-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030130261-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2003-07-10 | — | — | US | disclosed |
| US-20030008890-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2003-01-09 | — | — | US | disclosed |
| US-6462035-B1 | BINDING TO NEURONAL NICOTINIC ACETYLCHOLINE SPECIFIC RECEPTOR; MODULATING CHOLINERGIC FUNCTION; REDUCING NICOTINE ADDICTION; INFLAMMATORY AND IRRITABLE BOWEL SYNDROME, SPASTIC DYSTONIA, CHRONIC AND ACUTE PAIN, EATING DISORDERS | PFIZER INC. | 2002-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130261-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN3A | CHRNB2 297/4885CHRNA4 236/4885CHRNB4 524/4885 |
| US-20030008890-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, NR3C1 | CHRNB2 309/4885CHRNA4 220/4885CHRNB4 443/4885 |
| US-20040167149-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, NR3C1 | CHRNB2 309/4885CHRNA4 220/4885CHRNB4 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.